MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. Event ...

财务业绩 - 公司2024年第二季度总收入为XX美元，同比增长XX%[11] - 公司2024年第二季度净利润为XX美元，同比增长XX%[11] - 公司发布了未来XX季度的业绩指引，预计收入为XX-XX美元，净利润为XX-XX美元[11] 用户增长 - 公司用户数达到XX万，同比增长XX%[11] 产品和技术创新 - 公司推出了新产品XX和新技术XX，未来将继续加大研发投入[11] 市场拓展和并购 - 公司计划在未来XX年内进行市场扩张和并购，以提升市场份额[11] 成本优化和运营效率 - 公司将继续优化成本结构，提高运营效率，为股东创造更多价值[11] 管理层展望 - 公司管理层对未来发展前景保持乐观态度，将努力推动业务持续增长[11] - 公司将进一步加强与团队的沟通协作，共同推动公司战略实施[11]

临床试验进展 - 公司正在开发治疗阿尔茨海默病和帕金森病的主要产品候选药物Buntanetap[118] - 公司已完成两项1/2期临床试验,结果显示Buntanetap可降低神经毒性蛋白水平,改善认知功能和运动功能[119,120] - 公司已启动帕金森病3期临床试验和阿尔茨海默病2/3期临床试验,并在2023年完成了这两项试验的中期分析[122,123,124] - 公司计划在2026年前完成必要的关键性研究,并向FDA提交两个新药申请[125] 财务状况 - 公司目前现金和现金等价物不足以支持未来12个月的运营,需要通过多种融资方式筹集大量额外资金[127,128,129] - 2024年6月30日,公司现金及等价物余额为3,997.8千美元,预计无法支持未来12个月的运营[154] - 2024年4月,公司与ELOC购买方签订了ELOC融资协议,可发行最多2,051,428股普通股[155,156] - 2024年3月,公司进行了两次注册直接发行,共募集3,875.0千美元[157] - 2023年4月,公司向董事会成员和管理层进行了私募配售,募集1,065.0千美元[158] 费用变动 - 2024年第二季度研发费用同比下降2,477.0千美元,主要是由于临床试验成本的时间性差异[136] - 2024年第二季度管理费用同比增加479.9千美元,主要是由于股份支付费用和专业服务费用的增加[137,138] - 2024年上半年研发费用为12,307.3千美元,较2023年同期下降3,740.9千美元,主要由于临床试验支出时间性差异[148,149] - 2024年上半年一般及行政费用为3,265.1千美元,较2023年同期下降416.1千美元,主要由于专业服务费用减少[150] 其他财务指标 - 2024年6月30日三个月期间融资成本为1,346.1千美元,主要由于ELOC融资相关的发行成本和衍生工具公允价值变动[145] - 2024年6月30日三个月期间,认股权公允价值变动产生4,062.3千美元收益,主要由于公司股价下降导致负债公允价值下降[140] - 2024年6月30日三个月期间,利息收入为26.0千美元,较2023年同期下降196.6千美元,主要由于现金及等价物余额减少[141] - 2024年上半年,认股权公允价值变动产生10,761.0千美元收益,主要由于公司股价下降导致负债公允价值下降[152]

PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence, the Alzheimer's Disease Diagnostics And Therapeutics Market size is estimated at USD 7.70 billion in 2024, and is expected to reach USD 10.10 billion by 2029, growing at a CAGR of 5.57% during the forecast period (2024-2029). The report said: "The major factors driving the growth of the Alzheimer's disease diagnostics and therapeutics market are the increasing use of biomarker ...

PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The higher incidence of this neurodegenerative disorder has significantly elevated the demand for therapeutic solutions. Alzheimer's is characterized as a chronic brain condition that frequently results in dementia, particularly in older individuals. It adversely affects memory, cogn ...

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap. In 2016, the Company filed a patent covering the treatment of various ...

Annovis Bio (NYSE:ANVS) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson’s treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson’s, helping them retain and improve both motor and non-motor activities and cognitive functions. According to the data, buntanetap showed statistically significant improvements in cognitive ability in the overall population of Parkinson’s patient ...

文章核心观点 - 公司的新药物buntanetap在治疗帕金森病(PD)方面取得了积极的临床试验结果 [5] - buntanetap在改善PD患者的认知功能、运动功能和非运动功能方面均显示出显著疗效 [7][10][14] - buntanetap在PD患者中表现出良好的安全性 [16] 根据相关目录分别进行总结 认知功能改善 - 在整个入组人群中,安慰剂组出现认知功能下降,而buntanetap治疗组(10mg和20mg)维持基线水平,表明该药物在阻止认知功能下降方面具有统计学显著作用 [7] - 在轻度痴呆患者(MMSE 20-26)中,安慰剂组认知功能下降速度更快,而20mg buntanetap组显示出显著的认知改善 [8][9] 运动和非运动功能改善 - 在PD确诊超过3年的患者中,20mg buntanetap显著改善了MDS-UPDRS Part II、Part III、Part II+III和总分 [12] - 在姿势不稳和步态障碍(PIGD)患者中,buntanetap也显示出了同样的MDS-UPDRS改善效果 [14][15] 安全性 - buntanetap在早期和晚期PD患者中保持了一致的安全性概况,与之前的阿尔茨海默病数据一致 [16]

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3 ...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed ...